bearish
Square Pharmaceuticals (SQUARE BD): Too Many Competitors Spoil the Party for Covid-19 Oral Drug
203 Views29 Nov 2021 00:29
SUMMARY
- Square Pharmaceuticals (SQUARE BD) received approval for oral Covid-19 pill along with four other companies in Bangladesh, with no product or pricing differentiation.
- No immediate sign of export acceleration due to completion delay of Kenya plant, which targets to serve Common Market for Eastern and Southern Africa (Comesa) population of approximately 400 million.
- Recent top and bottom-line growth are lagging peers. With no immediate catalyst seen, investors should avoid the stock.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Square Pharmaceuticals (SQUARE BD): Recent Policy Changes Open Up International Opportunities27 Feb 2022
- Square Pharmaceuticals (SQUARE BD): Too Many Competitors Spoil the Party for Covid-19 Oral Drug29 Nov 2021
x